We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Labopharm Inc. today announced the completion of its previously announced public offering of 12,650,000 common shares, which includes exercise in full of the underwriters' over-allotment option.
Engineering and manufacturing conglomerate Honeywell International Inc. on Wednesday said its specialty materials unit sold a plant in Ireland to pharmaceutical supplier Sigma-Aldrich Corp. for an undisclosed price, completing Honeywell's exit from the pharmaceuticals business.
Two Pennsylvania law firms have filed class action lawsuits against Discovery Labs for allegedly misleading stockholders on Surfaxin's prospects for federal approval.
The first international clinical trial to treat women with recurring hereditary breast cancer has been launched in Europe, America, Australia and Israel.
Japanese drugmaker Astellas Pharma and U.S.-based FibroGen have entered into an exclusive licensing agreement for FG-2216 and FG-4592, drug candidates for anemia developed by FibroGen.
Biovail Corporation today announced that Biovail Pharmaceuticals, Inc. (BPI), the Company's wholly owned U.S. subsidiary, and AstraZeneca Pharmaceuticals LP have entered into an agreement for which BPI's specialty sales force will promote Zoladex 3.6mg (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the United States and Puerto Rico.
A bird flu vaccine being developed by San Diego-based Vical Incorporated protects mice and ferrets against the feared H5N1 avian influenza virus, the company said on Tuesday.
A provocative new theory suggests that one root cause of Alzheimer's disease is linked to diabetes a theory about to be tested in thousands of Alzheimer's patients given the diabetes drug Avandia in hopes of slowing brain decay.